在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用： (1) 接触人体组织或体液长达30天或更长时间； (2)“整形”（整容或重建）手术； (3) 生殖植入物或任何节育器械；或者 (4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。

STAYING AHEAD OF TRENDS2 1 3 4 5 WHAT ARE THE NEWEST POLYMER TECHNOLOGIES?

Avient expressly rejects the applicability of any additional, different, conflicting, or other terms and conditions or stipulations of Supplier. 1. Supplier warrants that the Goods provided do not contain any chemicals included on Schedule 1, Schedule 2, or Schedule 3 of the Chemical Weapons Convention and Chemical Weapons Convention Regulations and do not contain so-called Conflict Minerals nor result from processes utilizing Conflict Minerals. Indemnification and Liability 13.1 Supplier will indemnify, defend, and hold harmless Avient, its officers, directors, employees, agents, successors, assigns, customers and other vendors, and their respective present and future directors, officers, employees and agents from and against all liabilities, damages, claims, losses, costs, fees, expenses, penalties and injuries of any kind or nature (including court costs and reasonable attorneys’ and experts’ fees), arising out of or resulting in any way from: 1) Any breach by Supplier or a Supplier contractor/agent of any representation, warranty or obligation under the Agreement; 2) Any product liability and/or Avient Terms and Conditions of Purchase for Goods and/or Services product safety issue(s) related to the Goods; 3) Personal injury or death related to the Goods and/or Services hereunder; 3) Any loss or damage to property attributable to the Goods or Services; 4) Any negligent act, omission or willful misconduct of Supplier or a or Supplier contractor/agent; and 5) The failure of Supplier’s Goods or Services to comply with all international, state, federal and local laws, rules and regulations.

TERMS AND CONDITIONS These Terms and Conditions govern the sale of Products to another (“Buyer”) by Avient Corporation and its affiliates (“Seller”). 1. Kupujúci skontroluje výrobok okamžite po doručení, či nie je 1. Všeobecné obchodné podmienky (1. apríla 2024) Terms and Conditions (April 1, 2024)

WARUNKI Niniejsze Warunki regulują sprzedaż Produktów na rzecz drugiej strony („Kupujący”) przez Avient Corporation i jej podmioty powiązane („Sprzedający”). 1. By making a purchase order to Seller, Buyer confirms the foregoing to Seller. 1. Terms and Conditions (October 1, 2024) Warunki (1 października, 2024 r.)

TERMS AND CONDITIONS These Terms and Conditions govern the sale of Products to another (“Buyer”) by Avient Corporation and its affiliates (“Seller”). 1. Terms and Conditions (December 1, 2024) obligaciones y/o subcontratar la ejecución de las obligaciones del Vendedor en virtud de los presentes Términos sin el consentimiento del Comprador. Términos y Condiciones (1 de diciembre de 2024)

1. 公 公 公 公 公 公 公 公 公 公 公 公 ，公 公 公 公 公 公 公 公 ，公 公 公 公 公 公 ： 公 公 公 公 公 Avient 公 公 公 公 公 33587 公 公 公 公 ，公 公 公 公 44012 公 公 公 公 ： PRIVACY.OFFICER@AVIENT.COM 公 公 ：1-800-901-2078 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 。 公 公 公 公 公 公 公 公 ，公 公 公 公 公 公 公 公 公 公 公 "[avient.taleo.net]"，公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 公 ，公 公 公 公 RNPDP-PJP Nº [*]、” 公 公 公 公 ：2020 公 8 公 1 公 mailto:PRIVACY.OFFICER@AVIENT.COM https://privacyportal.onetrust.com/webform/b25cf7b1-a93a-4d26-8c84-ceda4d0ae91b/e180cbe4-d1b9-49bd-b621-cb5f6a0f42cb mailto:PRIVACY.OFFICER@AVIENT.COM

COMPREHENSIVE REGULATORY TESTING AND DOCUMENTATION Raw materials tested to: • ISO 10993-1 and USP , (biological evaluation) • European Pharmacopeia 3.1.3/3.1.5 (polyolefin —materials used for the manufacture of containers) • USP (polyethylene—plastic materials of construction) • ICH Q3D (elemental impurities) We provide Drug Master File (Type III) documentation and other supporting regulatory declarations that are relevant for the application.

ECert - 2023-09-20T092923.129.pdf Page 1 of 7 Validity of this certificate is based on the successful completion of the periodic surveillance audits of the management system defined by the above scope and is contingent upon prompt,written notification to ABS Quality Evaluations, Inc. of significant changes to the management system or components thereof.

General Purposes The general purposes of the Committee are to: • Oversee the Company’s overall executive compensation philosophy and objectives; • Discharge the Board’s responsibilities relating to compensation of the Company’s executive officers (for purposes of this Charter, “executive officers” means the Company’s Section 16 “officers” as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended); • Assist the Board in the discharge of its fiduciary responsibilities with regard to establishment of policies governing, and the implementation of, all aspects of executive officer compensation throughout the Company, including benefits and perquisites, and compensation for any other employees designated by the Committee for such purposes; • Discharge similar responsibilities with respect to the compensation of non-employee directors; • Review and discuss with management the Company’s disclosures in the Compensation Discussion and Analysis (the “CD&A”) required by rules and regulations of the Securities and Exchange Commission (the “SEC”) and recommend to the Board whether the CD&A should be included in the Company’s proxy statement or other applicable SEC filings; • Prepare a Compensation Committee Report for inclusion in the Company’s applicable filings with the SEC that complies with the rules and regulations of the SEC; and • Provide policy guidance and oversight on significant human resource policies and practices. 2 Duties and Responsibilities The Committee will: Executive Compensation and Incentives